Two oncology specialists, Epizyme and Clovis, have been punished for ongoing problems.
Sanofi needs more than Dupixent for its speciality care division to remain a bright spot.
Which groups might Boston Scientific bolt on next?
Glaxosmithkline is trying to reinvent itself as an oncology company – but it will need to make bolder deals if it wants to succeed.
Bayer's only remaining medical technology franchise is its radiology business.
Japanese group prefers M&A over license
GE arrives to the spin-out party fashionably late.
Cracking the cancer code.